Vir Biotechnology (VIR) closed at $13.13 on November 11, 2026, down 0.2% from the previous close, on volume of 1,230,733 shares (30-day average 1,970,508).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Jelly Roll or Calendar Double Straddle | 16-Oct-2610 P : 10 C|20-Nov-2610 P : 10 C | 2,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Wed, 11-Nov 4:20 AM ET)
Vir Biotechnology (VIR) Receives a Buy from Morgan Stanley
TipRanks (Tue, 10-Nov 8:17 AM ET)
Biggest stock movers Monday: NVDA, AMD, VIR, and more
Seeking Alpha News (Mon, 9-Nov 10:32 AM ET)
Vir Biotechnology shares rise on hepatitis D therapy data
Seeking Alpha News (Mon, 9-Nov 9:55 AM ET)
Vir Biotechnology Reports Positive Phase 3 Hepatitis Delta Trial Results
TipRanks (Mon, 9-Nov 9:02 AM ET)
AM Need to Know: Nvidia spy probe, Alphabet bets and more
Seeking Alpha News (Mon, 9-Nov 6:41 AM ET)
Vir Biotechnology (VIR) Gets a Buy from H.C. Wainwright
TipRanks (Mon, 9-Nov 6:35 AM ET)
Biggest stock movers Monday: NVDA, VIR, and more
Seeking Alpha News (Mon, 9-Nov 5:14 AM ET)
Vir Biotechnology reports positive hepatitis results, early signs of possible cure
Seeking Alpha News (Sun, 8-Nov 6:27 PM ET)
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Vir Biotechnology trades on the NASDAQ stock market under the symbol VIR.
As of November 11, 2026, VIR stock price declined to $13.13 with 1,230,733 million shares trading.
VIR has a beta of 1.16, meaning it tends to be more sensitive to market movements. VIR has a correlation of 0.07 to the broad based SPY ETF.
VIR has a market cap of $2.12 billion. This is considered a Mid Cap stock.
Last quarter Vir Biotechnology reported $-188,000 in Revenue and -$.57 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.19.
In the last 3 years, VIR traded as high as $14.45 and as low as $4.16.
The top ETF exchange traded funds that VIR belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
VIR has outperformed the market in the last year with a price return of +144.5% while the SPY ETF gained +12.6%. VIR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +47.7% and +13.5%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
VIR support price is $12.57 and resistance is $13.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIR shares will trade within this expected range on the day.
